Novo Nordisk Shares Rise After Hims & Hers Scraps Copycat GLP-1 Pill
Novo Nordisk shares jumped to a session high after Hims & Hers announced it would ditch its copycat GLP-1 weight-loss pill. The scrapped program sent Hims & Hers stock down 15%, reinforcing Novo’s dominant position in the obesity treatment market.
1. Hims & Hers Cancels Copycat Program
Hims & Hers halted development of its GLP-1 weight-loss candidate designed to rival Novo Nordisk’s Wegovy, citing strategic reprioritization and clinical uncertainties. The announcement triggered a 15% plunge in Hims & Hers stock as investors reassessed the company’s growth trajectory.
2. Novo Nordisk Stock Reaction
Novo Nordisk shares surged in early trading, reaching session highs after the competitor’s withdrawal removed a looming threat to its obesity franchise. Investors interpreted the move as a validation of Wegovy’s market leadership and long-term pricing power.
3. Market Implications
With Hims & Hers out of the GLP-1 race, Novo Nordisk is expected to defend its market share unchallenged through at least 2026. Analysts now project stronger earnings revisions for Novo’s obesity business and a reinforced pipeline focus on next-generation metabolic therapies.